Artificial intelligence in pharmacy

This template is being used in the wrong namespace. To nominate this talk page for deletion, go to Miscellany for deletion.

This article may incorporate text from a large language model. It may include hallucinated information, copyright violations, claims not verified in cited sources, original research, or fictitious references. Any such material should be removed, and content with an unencyclopedic tone should be rewritten. (May 2026) (Learn how and when to remove this template message)

Artificial intelligence in pharmacy refers to the application of artificial intelligence (AI) techniques across pharmaceutical research and practice, including drug discovery, drug delivery, safety monitoring, clinical decision support, and pharmacy operations.^[1][2] Machine learning, deep learning, and natural language processing have been applied to tasks ranging from molecular design to patient adherence monitoring, with the aim of reducing development costs, improving accuracy, and personalizing treatment.^[3]

Adoption has been uneven. Barriers include limited AI training among pharmacists, high infrastructure costs, and the risk of harm from models trained on unrepresentative data.^[4] Regulatory frameworks for AI-based pharmaceutical tools remain in active development across most jurisdictions.^[5]

Drug development is resource-intensive: bringing a single drug to market typically costs around $2.6 billion and takes 12–14 years.^[6] Machine learning algorithms have been applied to analyze molecular datasets to identify potential drug candidates, predict drug–target interactions, and optimize formulations.^[7][8]

Artificial neural networks and generative adversarial networks have been used in drug discovery tasks including virtual screening, structure-activity relationship modeling, and de novo molecule generation.^[9] Peptides designed using AI methods have shown activity against multidrug-resistant bacteria, and transcriptomic data from human cell lines has been used to train deep learning models to classify drugs by therapeutic properties.^[6]

Results in drug discovery have been mixed. AI models depend on the quality and diversity of their training data; those trained on narrow chemical libraries can fail to generalize to novel molecular scaffolds.^[8] The gap between high virtual screening hit rates and success in preclinical or clinical testing remains a persistent challenge, and the translation of computationally predicted candidates into approved drugs has been slower than early projections suggested.^[7]

AI methods including neural networks, principal component analysis, and neuro-fuzzy logic have been applied to identifying biological targets for pharmaceuticals and analyzing genetic information relevant to drug design.^[1] Computational models can predict how a formulation will behave in biological systems, helping narrow the field before laboratory synthesis begins.^[10]

Systems have been proposed that monitor patient response and adjust doses in real time based on individual physiology, with potential applications in chronic disease management. Research has also explored AI applications in targeted cancer treatments and oral vaccine delivery, areas where precise control over drug release kinetics is a design priority.^[11][10]

AI has been applied to predicting and detecting adverse drug reactions using techniques including knowledge graphs, logistic regression classifiers, and neural networks. A 2023 study developed a machine learning algorithm using knowledge graph analysis to classify known causes of adverse reactions.^[12] Natural language processing and deep learning models including long short-term memory (LSTM) networks have shown better performance than conventional methods for detecting opioid misuse, drawing on both structured data from electronic health records and unstructured sources such as clinical notes.^[5]

AI-based pharmacovigilance systems can scan large volumes of electronic health records and social media for drug safety signals at a scale not feasible with manual review.^[5] Limitations include difficulty distinguishing drug-related adverse events from unrelated conditions in free-text data, and the need for validated benchmarks to measure model performance against existing safety monitoring standards.^[12]

Machine learning systems trained on patient datasets can predict individual risk profiles, including potential allergies and drug–drug interactions, reducing the risk of harm in complex polypharmacy cases where the number of possible interactions exceeds what a clinician can readily assess.^[2][12] Personalized dosing models have been developed for drugs with narrow therapeutic windows — including anticoagulants and immunosuppressants — using patient-specific variables such as weight, renal function, and relevant genetic markers.^[2]

Prospective clinical validation of these systems has lagged behind their technical development. Most published evaluations report performance on retrospective datasets, and the regulatory pathway for AI-based clinical decision support tools in pharmacy varies by jurisdiction.^[5]

Robotic and AI-driven systems have been applied to dispensing accuracy and pharmacy logistics. At the UCSF Medical Center, robotic technology produced 350,000 medication doses with no dispensing errors recorded.^[6] Robots such as TUG assist with preparing and transporting medications and laboratory samples within hospital settings.^[13]

AI has also been applied to inventory management, with demand-forecasting systems predicting medicine requirements to reduce shortages and minimize waste from expired stock.^[13][5] In community pharmacy settings, AI tools have been used to flag potential prescription errors and alert pharmacists to drug–drug interactions before dispensing.^[13]

Confirming that patients take prescribed medications as directed is a persistent challenge in healthcare. AI-enabled tools including smart pillboxes, RFID tags, ingestible sensors, and video check-ins have been applied to this problem.^[12] Smart pillboxes record when they are opened, providing real-time adherence data that can be reviewed remotely by care teams. Ingestible sensors transmit a signal after dissolution, offering direct confirmation of ingestion rather than proxy measures such as pill count or self-report.^[12]

Several barriers limit AI adoption in pharmacy practice. Many published evaluations report model performance on retrospective datasets rather than prospective clinical outcomes, making it difficult to assess real-world benefit.^[4] Pharmacists have reported limited AI training and knowledge, and research facilities often lack the computational infrastructure required for model development and validation.^[4] Models trained on biased or unrepresentative datasets can produce misleading results with direct patient safety consequences.^[12]

Regulatory frameworks for AI-based pharmaceutical tools are in active development. In the United States, the Food and Drug Administration (FDA) has issued guidance on AI and machine learning-based software as a medical device, addressing requirements for pre-market review and post-market performance monitoring.^[5] The European Medicines Agency has published discussion papers on the use of AI across the medicines development lifecycle, with particular attention to transparency in model training and validation.^[4] The absence of harmonized international standards creates compliance complexity for developers operating across multiple jurisdictions.^[5]

AI adoption raises data privacy and security concerns, including the risk of exposing sensitive patient information through data breaches.^[2] Algorithmic bias presents a related hazard: a model trained on an unrepresentative patient population may generate unsuitable treatment recommendations for patients not reflected in its training data, with potential for disparate outcomes across demographic groups.^[12] The opacity of some machine learning models, particularly deep neural networks, limits clinicians' ability to interpret or contest a recommendation, raising questions of accountability when a model-assisted decision results in patient harm.^[5]

Responses proposed in the literature include AI-focused education programs for pharmacists, increased public funding for healthcare AI research, encryption and governance frameworks for patient data, and regulatory requirements to prevent the use of biased training datasets.^[4] Greater transparency about training data provenance, model architecture, and validation methodology has also been recommended, including disclosure requirements in regulatory submissions.^[5]

Research groups have called for tighter integration between AI systems and electronic health records to reduce healthcare costs and improve continuity of care across settings.^[2] International collaboration through shared AI frameworks and federated learning approaches has been proposed to address data scarcity in underrepresented patient populations and accelerate validation across institutions.^[5]

0.00 (0 votes) Original source: https://en.wikipedia.org/wiki/Artificial intelligence in pharmacy. Read more